Tags : Soft Tissue Sarcoma

Taiwan Liposome’s TLC178 Receives EMA’s ODD for Soft Tissue Sarcoma

Shots: The ODD follows P-I/II study assessing TLC178 in patients with advanced malignancies in adults and has resulted in no dose-limiting toxicity till date The EMA’s Orphan Drug Designation (ODD) is granted to the therapies offering life-threatening condition affecting ≤5 in 10,000 persons in EU, with no approved treatment and receiving 10-year of marketing exclusivity […]Read More

Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III

Shots: The P-III ANNOUNCE study involves assessing of Lartruvo + doxorubicin following lartruvo monothx vs doxorubicin + PBO following PBO monothx in patients with advanced or metastatic STS The study didn’t meet 1EP as OS showing no difference in survival rate with no safety signals observed; AEs (all grades; grade 3-4) fatigue (69%,9% vs 3% […]Read More